Quinolines and derivatives
Apexbio Technology LLC GDC-0449 (Vismodegib) 879085-55-9 200mg
GDC-0449 (Vismodegib CAS 879085-55-9) is a small molecule that selectively inhibits the Hedgehog (Hh) signaling pathway by binding to the Smoothened (SMO) receptor thus preventing downstream activation of Hh target genes implicated in cellular proliferation and differentiation This compound emerged from screening small-molecule libraries followed by medicinal chemistry optimization Preclinical evaluation demonstrated antitumor activity in murine models of medulloblastoma and xenograft models derived from human colon and pancreatic cancers Currently GDC-0449 is under investigation for locally advanced and metastatic solid tumors
Apexbio Technology LLC Torin 2 1223001-51-1 200mg
Torin 2 (CAS 1223001-51-1) is a selective orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) exhibiting an EC50 of approximately 0 25 nM Structurally improved from Torin 1 Torin 2 interacts via hydrogen bonding with residues V2240 and Y2225 in mTOR and two additional interactions between its aniline amino group and residues D2195 and D2357 enhancing potency and pharmacokinetic properties It displays high selectivity for mTOR over phosphoinositide 3-kinases (PI3Ks) and other protein kinases by nearly 800-fold Due to these properties Torin 2 is extensively studied in oncological research targeting mTOR signaling pathways
Apexbio Technology LLC BMS-626529 701213-36-7 200mg
BMS-626529 is a small molecule inhibitor designed to block HIV-1 attachment to host cells Its mechanism involves binding to the viral envelope protein gp120 thereby hindering gp120-mediated interactions with CD4 receptors on CD4 T cells and preventing initial viral entry In cell-based assays BMS-626529 shows strain-specific antiviral activity with IC50 values mostly below 10 nM and notably low picomolar IC50 against highly susceptible HIV-1 isolates This molecule serves as a research tool to investigate HIV-1 entry inhibition and virus-host interaction mechanisms in biomedical studies
Apexbio Technology LLC MHY1485 326914-06-1 200mg
MHY1485 (CAS 326914-06-1) is a potent activator of mammalian target of rapamycin (mTOR) a serine/threonine kinase critical for cellular growth metabolism and survival pathways By activating mTOR signaling MHY1485 inhibits autophagy initiation and disrupts the fusion step between autophagosomes and lysosomes resulting in accumulation of autophagic marker LC3-II and enlarged autophagic structures In cultured rat Ac2F hepatic cells MHY1485 suppresses basal and starvation-induced autophagic flux Additionally MHY1485 treatment promotes ovarian follicular development and increases explant growth in mouse ovarian culture models providing a useful tool in biomedical research of mTOR signaling and reproductive biology
Apexbio Technology LLC SKF38393 HCl 62717-42-4 200mg
SKF38393 HCl is a selective dopamine D1 receptor agonist exhibiting activity through direct binding and stimulation of D1 receptors Activation of D1 receptors primarily induces adenylyl cyclase stimulation and increases cAMP-dependent protein kinase signaling subsequently modulating neuronal differentiation growth and dopamine-mediated functional responses Experimental evidence indicates that SKF38393 administration impacts gene expression patterns related to dopamine receptor-sensitive neuronal pathways and neuropeptides Additionally in vitro studies report SKF38393 to inhibit proliferation of certain tumor cell lines exemplified by decreased cell growth in breast carcinoma-derived MCF-7 cells at submicromolar concentrations It is widely utilized as a pharmacological tool in neuroscience and oncology research
Apexbio Technology LLC Belinostat (PXD101) 414864-00-9 200mg
Belinostat (PXD101) is a hydroxamic acid-based inhibitor targeting histone deacetylase (HDAC) enzymes Its mechanism involves the suppression of HDAC enzymatic activity leading to increased acetylation of histone proteins H3 and H4 within cells In biochemical assays using Hela cell extracts belinostat exhibits inhibitory activity against HDAC with an IC50 value of approximately 27 nM In tumor cell culture models belinostat induces cytotoxicity and represses cellular proliferation with reported IC50 values ranging roughly from 0 5 M to 10 M varying by cell type and origin making it suitable for research on epigenetic modulation in oncology specifically in studies of bladder prostate and related cancer cell lines
Medchemexpress LLC RCGD423 200mg | 108237-91-8 | 331.23 g/mol | 200 MG
RCGD423 is a small-molecule gp130 modulator used in research to prevent articular cartilage degeneration and promote repair. It modulates gp130 signaling and activates downstream JAK/STAT pathways, and has been applied in cellular and animal studies to evaluate cartilage protection and repair mechanisms.
- Modulates gp130 signaling and activates JAK/STAT pathways.
- Demonstrated disease-modifying activity in cartilage injury and degeneration models.
- High purity listed (99.92%), suitable for biochemical and cellular assays.
- Chemical formula C15H11BrN2S; molecular weight 331.23 g/mol.
- For research use only; not for human or clinical use.
Medchemexpress LLC RU.521 100mg | 2262452-06-0 | 100 MG
RU.521 is a small-molecule inhibitor of cyclic GMP-AMP synthase (cGAS) used in research to suppress cGAS-mediated interferon signaling. It is supplied as a high-purity solid and is provided in multiple sizes and formulations for in vitro and cellular studies.
- High purity (99.95%) for reproducible results.
- Potent, selective inhibition of cGAS in cellular assays.
- Available in multiple sizes and DMSO solution formats for flexibility.
- Stable as a powder at -20°C for long-term storage.
- Molecular weight 415.23; formula C19H12Cl2N4O3.
Medchemexpress LLC Sugar-modified guanosine analogue | 2481279-61-0 | 99.9% | 614.54 | C25H33F2N6O8P | 5 MG
AL-611 is a research-use small-molecule HCV NS5B polymerase inhibitor described as a sugar-modified guanosine analogue with potent antiviral activity (EC50 = 5 nM). It is supplied as a high-purity solid and is intended for laboratory research only, not for human or clinical use.
- Potent HCV NS5B polymerase inhibition (EC50 = 5 nM).
- Sugar-modified guanosine analogue class of compound.
- Molecular weight 614.54 g·mol-1.
- Chemical formula C25H33F2N6O8P.
- High purity, reported as 99.9% by HPLC.
- Available in small-milligram sizes, with a 10 mM in 1 mL DMSO solution option.
- For research use only; not for human or clinical use.
![Medchemexpress LLC 3-piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]am | 2178049-58-4 | 98.8% | 522.55 | C27H28F2N6O3 | 5 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000221277.png-250.jpg)
Medchemexpress LLC 3-piperidinecarboxamide, 1-(cyclopropylmethyl)-4-[[[5-(2,4-difluorophenyl)-3-isoxazolyl]carbonyl]am | 2178049-58-4 | 98.8% | 522.55 | C27H28F2N6O3 | 5 MG
ACT-1004-1239 is a potent, selective, orally active CXCR7 (ACKR3) antagonist supplied for research use. It shows nanomolar potency in biochemical assays and has demonstrated target engagement and pharmacological effects in preclinical models, including modulation of CXCL12/CXCL11 signaling and efficacy in rodent disease models. Supplied formats support both in vitro and in vivo study designs.
- Potent CXCR7 antagonism with reported IC50 of 3.2 nM.
- High purity suitable for research applications.
- Available as solid and 10 mM DMSO solution for convenient use.
- Appropriate for in vitro and in vivo pharmacology studies.
- For research use only; not for human or veterinary use.
Medchemexpress LLC Dosimertinib-d5 mesylate | 2403760-72-3 | 99.4% | 600.74 g·mol⁻1 | C29H32D5N7O5S | 5 MG
Dosimertinib-d5 mesylate is the deuterated mesylate salt of an EGFR inhibitor intended for preclinical research. It is reported to reduce phosphorylation of EGFR and ERK, show antiproliferative and antitumor activity in model systems, and is used in studies of non-small-cell lung cancer and EGFR signaling pathways.
- Deuterated small molecule designed for EGFR pathway research.
- Mesylate salt form with improved handling and solubility characteristics.
- Demonstrated decrease in p-EGFR and p-ERK levels in vitro.
- Shows antiproliferative and antitumor activity in preclinical models.
- Supplied in a 5 mg package suitable for analytical and in vitro studies.
![Medchemexpress LLC N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 1MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000231879.png-250.jpg)
Medchemexpress LLC N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 1MG
N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 1MG
![Medchemexpress LLC N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 50MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000231888.png-250.jpg)
Medchemexpress LLC N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 50MG
N-(1-benzyl-2,3-dihydro-1H-pyrrolo[2,3-b]quinolin-4-yl)-2-phenylacetamide | 365565-02-2 | 99.3% | 50MG
![Medchemexpress LLC Pyrimido[4,5-d]pyrimidinone derivative (1-cyclobutyl, 2,6-dimethylphenyl, 2-methoxy-4-piperazinyl) | 2172617-15-9 | 99.8% | 100 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000232299.png-250.jpg)
Medchemexpress LLC Pyrimido[4,5-d]pyrimidinone derivative (1-cyclobutyl, 2,6-dimethylphenyl, 2-methoxy-4-piperazinyl) | 2172617-15-9 | 99.8% | 100 MG
YKL-06-061 is a potent, selective, second-generation salt-inducible kinase (SIK) inhibitor for research use. It displays low-nanomolar activity against SIK isoforms and is supplied as a purified small-molecule reagent.
- Potent SIK inhibition (SIK1 = 6.56 nM, SIK2 = 1.77 nM, SIK3 = 20.5 nM).
- High reported purity (approximately 99.8% by HPLC).
- Molecular formula C30H37N7O2; molecular weight 527.66 g/mol.
- Available in multiple sizes and formats, including milligram quantities and a 10 mM solution in DMSO.
- For research use only; not for human or veterinary applications.
![Medchemexpress LLC 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate | 406205-74-1 | MFCD09027365 | 98.6% | 453.36 g/mol | C18H13F6NO4S | 10 MG](https://assets.fishersci.com/TFS-Assets/CCG/product-images/5000214106.png-250.jpg)
Medchemexpress LLC 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate | 406205-74-1 | MFCD09027365 | 98.6% | 453.36 g/mol | C18H13F6NO4S | 10 MG
Bay 59-3074 is a selective cannabinoid CB1/CB2 receptor partial agonist with demonstrated analgesic activity. It binds human CB1 and CB2 receptors (Ki 48.3 nM and 45.5 nM) and shows antihyperalgesic and antiallodynic effects in rodent pain models.
- Selective CB1/CB2 receptor partial agonist.
- High affinity for human CB1 (Ki ~48.3 nM) and CB2 (Ki ~45.5 nM).
- Demonstrated antihyperalgesic and antiallodynic effects in rodent models.
- High purity (98.6%) and solid, white to off-white appearance.
- Highly soluble in DMSO (≥ 100 mg/mL).
- Stable when stored as powder at -20°C (up to 3 years) or 4°C (up to 2 years).